Medical News Today, 6 Apr 2009
A*STAR's Singapore Immunology Network (SIgN) and Swiss company Cytos Biotechnology Ltd (Cytos) have pledged to work together to develop fully human monoclonal antibodies for combating and managing the Enterovirus 71 (EV71), one of the two most common viruses responsible for hand, foot and mouth disease (HFMD) in Singapore. This collaborative research is especially timely for Singapore, which has seen seasonal outbreaks[1] of this highly infectious disease that largely afflicts young children. There is currently no specific treatment available for HFMD.
Read More
